ED-71 Chugai.
Chugai is developing ED-71, an orally available vitamin D3 derivative, for the potential treatment of osteoporosis. By December 2003, the compound had entered phase III trial for the prevention of fracture.
Ahmed
Intekhab
I
Department of Endocrinology and Metabolism, Thomas Jefferson Medical College and University, 1020 Locust Street, Philadelphia, PA 19107, USA. Intekhab.Ahmed@jefferson.edu
D000818:Animals; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy / Q000517:prevention & control; D018167:Receptors, Calcitriol / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D014807:Vitamin D / Q000031:analogs & derivatives
D018167:Receptors, Calcitriol; D014807:Vitamin D; D002117:Calcitriol; C547512:eldecalcitol